Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

Naval Daver; Aditi Shastri; Tapan Kadia; Kate Newberry; Naveen Pemmaraju; Elias Jabbour; Linghsa Zhou; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek

doi:10.1016/j.leukres.2014.06.015

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

Naval Daver
, Aditi Shastri
, Tapan Kadia
, Kate Newberry
, Naveen Pemmaraju
, Elias Jabbour
, Linghsa Zhou
, Sherry Pierce
, Jorge Cortes
, Hagop Kantarjian
, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. < 10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

Original language	English (US)
Pages (from-to)	1126-1129
Number of pages	4
Journal	Leukemia Research
Volume	38
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2014.06.015
State	Published - Sep 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anemia
Myelofibrosis
Pomalidomide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2014.06.015

Cite this

@article{f737439409ef411d9cf2745fbd3fbfc3,

title = "Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia",

abstract = "We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. < 10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21\%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.",

keywords = "Anemia, Myelofibrosis, Pomalidomide",

author = "Naval Daver and Aditi Shastri and Tapan Kadia and Kate Newberry and Naveen Pemmaraju and Elias Jabbour and Linghsa Zhou and Sherry Pierce and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",

note = "Funding Information: This research is supported in part by a Cancer Center Support Grant from the National Cancer Institute (CA016672) to MD Anderson Cancer Center. ND, AS, KN, and SV wrote the paper; SV and HK designed and coordinated the clinical trial; SV, HK, TK, NP, EJ, JC enrolled the patients and conducted the research; and LZ, SP and ND analyzed the data and performed the statistics. All of the authors participated in the discussion and have reviewed and approved the current version of the manuscript.",

year = "2014",

month = sep,

doi = "10.1016/j.leukres.2014.06.015",

language = "English (US)",

volume = "38",

pages = "1126--1129",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "9",

}

TY - JOUR

T1 - Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

AU - Daver, Naval

AU - Shastri, Aditi

AU - Kadia, Tapan

AU - Newberry, Kate

AU - Pemmaraju, Naveen

AU - Jabbour, Elias

AU - Zhou, Linghsa

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

N1 - Funding Information: This research is supported in part by a Cancer Center Support Grant from the National Cancer Institute (CA016672) to MD Anderson Cancer Center. ND, AS, KN, and SV wrote the paper; SV and HK designed and coordinated the clinical trial; SV, HK, TK, NP, EJ, JC enrolled the patients and conducted the research; and LZ, SP and ND analyzed the data and performed the statistics. All of the authors participated in the discussion and have reviewed and approved the current version of the manuscript.

PY - 2014/9

Y1 - 2014/9

N2 - We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. < 10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

AB - We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. < 10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

KW - Anemia

KW - Myelofibrosis

KW - Pomalidomide

UR - https://www.scopus.com/pages/publications/84906934354

UR - https://www.scopus.com/pages/publications/84906934354#tab=citedBy

U2 - 10.1016/j.leukres.2014.06.015

DO - 10.1016/j.leukres.2014.06.015

M3 - Article

C2 - 25047979

AN - SCOPUS:84906934354

SN - 0145-2126

VL - 38

SP - 1126

EP - 1129

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this